Background: A variety of regulatory approaches including immune modulation have been explored as approaches to either eradicate antitumor response or induce suppressive mechanism in the
glioblastoma microenvironment. Thus, the study of immune-related
long noncoding RNA (
lncRNA) signature is of great value in the diagnosis, treatment, and prognosis of
glioblastoma. Methods:
Glioblastoma samples with
lncRNA sequencing and corresponding clinical data were acquired from the
Cancer Genome Atlas (TCGA) database. Immune-lncRNAs co-expression networks were built to identify immune-related lncRNAs via Pearson correlation. Based on the median risk score acquired in the training set, we divided the samples into high- and low-risk groups and demonstrate the survival prediction ability of the immune-related
lncRNA signature. Both principal component analysis (PCA) and gene set enrichment analysis (GSEA) were used for immune state analysis. Results: A cohort of 151
glioblastoma samples and 730 immune-related genes were acquired in this study. A five immune-related
lncRNA signature (AC046143.1, AC021054.1, AC080112.1, MIR222HG, and
PRKCQ-AS1) was identified. Compared with patients in the high-risk group, patients in the low-risk group showed a longer overall survival (OS) in the training, validation, and entire TCGA set (p = 1.931e-05, p = 1.706e-02, and p = 3.397e-06, respectively). Additionally, the survival prediction ability of this
lncRNA signature was independent of known clinical factors and molecular features. The area under the ROC curve (AUC) and stratified analyses were further performed to verify its optimal survival predictive potency. Of note, the high-and low-risk groups exhibited significantly distinct immune state according to the PCA and GSEA analyses. Conclusions: Our study proposes that a five immune-related
lncRNA signature can be utilized as a latent
indicator of prognosis and potential therapeutic approach for
glioblastoma.